Alzheimer’s breakthrough: Scientists restore two hours of sleep without clearing brain plaques

Key Points:

• Researchers at the University of Kentucky discovered that microglia, the brain's immune cells responding to amyloid plaques, are the main drivers of sleep loss in an Alzheimer's disease animal model, challenging prior beliefs that plaques or damaged neurons were the primary cause.
• By temporarily eliminating about 87% of microglia using the drug Pexidartinib, mice with Alzheimer's pathology regained over two hours of sleep per day and experienced longer restorative non-REM sleep, despite unchanged plaque levels.
• The study revealed that early amyloid plaque accumulation triggers a lasting sleep deficit, with Alzheimer's selectively reducing restorative non-REM sleep, which is critical for brain repair and toxin clearance, potentially creating a harmful cycle of worsening damage.
• Researchers propose that EEG technology could serve as a noninvasive, affordable biomarker to distinguish Alzheimer's-related brain changes from normal aging and enable earlier disease detection through portable monitoring systems.
• Ongoing work aims to develop treatments that calm microglial overactivity without removing the cells, exploring existing drugs like Metformin and Stiripentol to restore healthy sleep and improve cognitive function before significant memory loss occurs.